8 research outputs found
Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment
Interferon alfa (IFN-a) is the primary treatment for
chronic hepatitis B. The standard duration of IFN-a therapy
is considered 16 weeks; however, the optimal treatment
length is still poorly defined. We evaluated the efficacy and
acceptability of prolonged IFN-a treatment in patients with
chronic hepatitis B. To investigate whether treatment prolongation
could enhance the rate of hepatitis B e antigen
(HBeAg) seroconversion, we conducted a prospective, controlled,
multicenter trial in wh
Rosiglitazone: possible complications and treatment of non-alcoholic steatohepatitis (NASH)
In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks:pooled analysis of two Scandinavian trials
AIM: To compare 14 and 24 weeks treatment to patients with HCV genotype 2 or 3 infection and rapid virological response (RVR). MATERIALS AND METHODS: Patients included in two Scandinavian trials, one nonrandomized pilot trial (n=122) and one randomized controlled trial (RCT) (n=428) were entered into a pooled database. In both trials treatment naĂŻve patients with genotype 2 or 3 were treated with pegylated interferon alpha 2b (1.5 mug/kg, subcutaneous) weekly and ribavirin (800-1400 mg, orally) daily. Primary endpoint was sustained virological response (SVR). RVR was defined as HCV RNA less than 50 IU/ml after 4 weeks of treatment. In the pilot trial all patients with RVR were treated for 14 weeks and in the RCT patients with RVR were randomised to either 14 or 24 weeks treatment. Patients treated per protocol were included in the primary analysis. The noninferiority margin was set to be 10% between the two groups with a one-sided 5% significance level. RESULTS: In patients with RVR and genotype 2 or 3 SVR was obtained in 181 of 199 (91.0%) and 93 of 98 (94.9%) after 14 and 24 weeks treatment, respectively. The observed difference in SVR rates was 3.9% (90% confidence interval: +1 to -8.8). The relapse rate was highest among those older than 40 years and those with genotype 3 and high viral load, but prolongation of treatment from 14 to 24 weeks did not reduce the relapse rate substantially in any of these groups. CONCLUSION: In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks
Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin
Recommended from our members
Increased Sympathetic Activity in Cirrhosis
To the Editor:
Like Bichet et al. (Dec. 16 issue)
1
we have recently observed that sympathetic nervous activity, as assessed by the plasma norepinephrine concentration, is dramatically increased in decompensated cirrhosis.
2
Since the kidney releases norepinephrine into the peripheral circulation in this condition,
2
we have suggested that increased sympathetic nervous activity may be of importance in the renal cortical vasoconstriction in decompensated cirrhosis.
3
The results reported by Bichet et al. support the view that the sympathetic nervous system is an important component of the homeostatic mechanisms in advanced liver disease. These authors observed a relation between the plasma norepinephrine level, . . .
No extract is available for articles shorter than 400 words